

Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	March 13, 2023

**Aemcolo™ (rifamycin)**

**LENGTH OF AUTHORIZATION:** 3 days

**REVIEW CRITERIA:**

- Patient must be  $\geq$  18 years of age.
- Patient must have known or strongly suspected travelers' diarrhea due to non-invasive strains of *Escherichia coli* (*E. coli*).
- Diarrhea is NOT accompanied by fever or bloody stools.
- Patient does not have known hypersensitivity to rifamycin, any other medications in the rifamycin class (e.g., rifaximin), or any components of Aemcolo.

**DOSING AND ADMINISTRATION:**

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as 194 mg delayed-release tablet.